Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center



A Dose Escalation Trial of ATRC-101 in Adults With Advanced Solid Malignancies

Multiple Cancer Types

ATRC-101-A01 is a Phase 1b, open-label dose escalation trial of ATRC-101, an engineered fully human immunoglobulin G, subclass 1 (IgG1) antibody derived from a naturally occurring human antibody. The safety, tolerability, PK, and biological activity of ATRC-101 will be characterized when administered every two weeks (Q2W) or every 3 weeks (Q3W) as a monotherapy or in combination with other anticancer agents.
Breast, Colon, Lung, Melanoma, Non Small Cell, Ovarian, Phase I, Rectal
I
Berlin, Jordan
NCT04244552
VICCPHI2040

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: